Sumary of Tenofovir alafenamide prevents mother-to-infant HBV transmission:
- November 15, 2021 1 min read Source/Disclosures Published by: Source: Zeng QL.
- Back to Healio Tenofovir alafenamide therapy was safe, well-tolerated and prevented the transmission of hepatitis B virus from pregnant mothers to infants, according to research presented at The Liver Meeting Digital Experience.
- In a multicenter study, researchers aimed to investigate the safety and effectiveness of TAF therapy in preventing mother-to-child HBV transmission.
- Enrolled mothers received either TAF (n = 103) or TDF (n = 104) according to patient preference and all infants received immunoprophylaxis.
- For mothers, Zeng and colleagues evaluated perinatal adverse events, complications, ALT flare and changes in kidney function at delivery, postpartum month 3 and postpartum month 6. Infant safety assessments included evaluation of structural defects at birth, Apgar scores and abnormal conditions from birth to 7 months.
- Mothers and infants were closely monitored until at least 7 months postpartum;
- The most common adverse event was nausea which occurred in 29.1% and 31.7% of mothers and the most common maternal complication was premature rupture of membranes (12.6% and 13.5%).
- They further observed no congenital defects among infants as well as normal physical and neurological development through follow-up;